RecruitingEarly Phase 1NCT06628154
Losartan and Emotional Learning
The Effects of Single-dose Losartan on Cognitive Flexibility and Learning in Healthy Adults: a Randomised Controlled Study
Sponsor
University of Oxford
Enrollment
60 participants
Start Date
Aug 14, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in healthy volunteers.
Eligibility
Min Age: 18 YearsMax Age: 50 Years
Inclusion Criteria5
- Willing and able to provide informed consent
- Aged 18-50 years
- Score of or below 45 on the Dimensional Anhedonia Rating Scale (DARS; Rizvi et al., 2015)
- Sufficient written and spoken English skills to understand what the study involves, and to complete the questionnaires
- Non- or light-smoker (5 cigarettes a day)
Exclusion Criteria12
- Past or present DSM-5 axis-I diagnosis (based on SCID results at screening) other than anxiety disorder, dysthymia or unipolar depression
- First-degree family member with severe psychiatric illness
- CNS-medication last 6 weeks (including as part of another study)
- Current blood pressure or other heart medication (especially aliskiren or beta blockers)
- Diagnosis of intravascular fluid depletion or dehydration
- History of angioedema
- Impaired kidney function (based on self-report)
- Very low blood pressure (defined as repeated (at least three consecutive measurements) measures of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90/50 mmHg (in accordance with established standard definitions: DOI 10.1186/s12887-016-0633-7))
- Lifetime history of epilepsy or other neurological disease (e.g. autism, ADHD)
- Lifetime history of systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study
- Significant loss of hearing that is not corrected with a hearing device
- Women: pregnancy, breast-feeding
Interventions
DRUGLosartan potassium 50mg
Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo
OTHERPlacebo
Single tablet encapsulated identically to losartan
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06628154